Affordable Access

Publisher Website

Clinical applications of Gallium-68

Elsevier Ltd
DOI: 10.1016/j.apradiso.2013.01.039
  • Pet
  • Radiopeptides
  • Somatostatin Receptor
  • Neuroendocrine Tumor
  • Clinical Trials
  • Medicine
  • Pharmacology


Abstract Gallium-68 is a positron-emitting radioisotope that is produced from a 68Ge/68Ga generator. As such it is conveniently used, decoupling radiopharmacies from the need for a cyclotron on site. Gallium-68-labeled peptides have been recognized as a new class of radiopharmaceuticals showing fast target localization and blood clearance. 68Ga-DOTATOC, 8Ga-DOTATATE, 68Ga-DOTANOC, are the most prominent radiopharmaceuticals currently in use for imaging and differentiating lesions of various somatostatin receptor subtypes, overexpressed in many neuroendocrine tumors. There has been a tremendous increase in the number of clinical studies with 68Ga over the past few years around the world, including within the United States. An estimated ∼10,000 scans are being performed yearly in Europe at about 100 centers utilizing 68Ga-labeled somatostatin analogs within clinical trials. Two academic sites within the US have also begun to undertake human studies. This review will focus on the clinical experience of selected, well-established and recently applied 68Ga-labeled imaging agents used in nuclear medicine.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Gallium-68: a systematic review of its nononcologi...

on Nuclear Medicine Communication... September 2013

PET/CT with 68Gallium-DOTA-peptides in NET: An ove...

on European Journal of Radiology Jan 01, 2011

Clinical applications of gallium in oncology

on International Journal of Nucle... Jan 01, 1981

Clinical applications of gallium in oncology.

on International Journal of Nucle... 1981
More articles like this..